You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨騰盛博藥-B(02137.HK)高開4.65% 國藥控股達成戰略合作 首個國產新冠抗體藥物加速生產
格隆匯3月30日丨騰盛博藥-B(02137.HK)高開4.65%,報9.9港元,總市值72億港元。騰盛博藥宣佈,其旗下控股公司騰盛華創醫藥技術(北京)有限公司與國藥控股股份有限公司達成戰略合作,雙方將共同推進公司長效新冠單克隆中和抗體安巴韋單抗/羅米司韋單抗聯合療法在中國的商業化進程,包括藥品儲備、渠道分銷、區域准入、及其它創新業務合作。此前的2021年12月8日晚間,安巴韋單抗/羅米司韋單抗聯合療法獲得國家藥品監督管理局上市批准。該抗體藥物由清華大學醫學院張林琦教授團隊、清華大學生命學院王新泉教授團隊與深圳市第三人民醫院張政教授團隊、騰盛華創共同研發。該藥系我國首個自主研發的抗新冠病毒抗體藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account